Prevalence of the Phelan-McDermid Syndrome in Spain
e202012121
Keywords:
Phelan-McDermid Syndrome, Prevalence, Sex, Age, DiagnosisAbstract
Background: Phelan-McDermid syndrome is a rare genetic condition caused by a deletion of the terminal end of chromosome 22 in the 13.3 region, as well as, by point mutations within SHANK3 gene. The aims of this research were to determine the prevalence of the disease in the Spanish population, to establish the geographical distribution of the syndrome among the different autonomous communities, to elucidate the age range that affects more patients, to study the disease-sex relationship, as well as the age at diagnosis.
Methods: For the research, patients diagnosed with the disease for twelve years were recruited throughout the Spanish territory. The clinical patient information was obtained from the referral doctors using two standardized questionnaires completed with data from the medical reports and the interview with the parents. The molecular diagnosis of the disease was carried out using different formats of microarrays. Data were processed using Microsoft Excel and Statgraphics Centurion XVII.
Results: Currently in Spain there are 201 people diagnosed with the disease. Currently in Spain there are 201 people diagnosed with the disease, its prevalence being 4x10-4/10,000 inhabitants. The community with the most diagnosed patients was Madrid and there were no significant differences in terms of sex and disease, the mean age at diagnosis was around 6.67 years.
Conclusions: The prevalence of the disease in Spain is very low, and it can be stated that it is very likely that there are more people with this syndrome in the population.
Downloads
References
Kolevzon A, Angarita B, Bush L, Wang AT, Frank Y, Yang A et al. Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring. J. Neurodev. Disord. 2014; 6: 39.
Costales JL, Kolevzon A. Phelan–McDermid Syndrome and SHANK3: Implications for treatment. Neurotherapeutics. 2015; 12: 620–630.
Anderlid BM, Schoumans J, Anneren G et al. FISH-mapping of a 100-kb terminal 22q13 deletion. Hum Genet 2002; 110: 439–443.
Tabet A-C, Rolland T, Ducloy M, Lévy J, Buratti J, Mathieu A et al. A framework to identify contributing genes in patients with Phelan-McDermid syndrome. NPJ Genom. Med. 2017;2(1).
Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, Selicorni A et al. Disruption of the ProSAP2 gene in at (12;22) (q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am. J. Hum. Genet. 2011; 69: 261-268.
Luciani JJ, de Mas P, Depetris D, Mignon-Ravix C, Bottani A, Prieur M et al. Telomeric 22q13 deletions resulting from rings, simple deletions, and translocations: cytogenetic, molecular, and clinical analyses of 32 new observations. J. Med. Genet. 2003; 40: 690-696.
Wilson HL, Wong ACC, Shaw SR, Tse WY, Stapleton GA et al. Molecular characterization of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/ PROSAP2 in the major neurological symptoms. J. Med. Genet. 2003; 40:575–584.
Phelan MC. Deletion 22q13.3 syndrome. Orphanet J. Rare Dis. 2008; 3: 14.
Hernández-Gómez M, Meléndez-Hernández R, Ramírez-Arroyo E, Mayén-Molina DG. Síndrome de Phelan-McDermid: reporte de un caso y revisión de la literatura. Acta Pediatr. Mex. 2018; 39(1):42-51.ICAL
Verhoeven WMA, Egger JI, Cohen-Snuijf R, Kant SG, de Leeuw N. (2013). Phelan-McDermid syndrome: clinical report of a 70-year-old woman. Am. J. Med. Genet. 2013; Part A 161A: 158-161.
Downloads
Published
How to Cite
License
Copyright (c) 2020 Bárbara Gómez Taylor, Mari Luz Moreno Sancho, Eraci Drehmer Rieger, Sandra Carrera Juliá, Julián Nevado, Francisca Sempere Ferre
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
